On April 30, 2021 Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, reported that the Safety Review Committee meeting to evaluate the per protocol Interim Safety Analysis for the VB C-02 trial concluded to continue the recruitment as planned (Press release, Vaccibody, APR 30, 2021, View Source [SID1234578821]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investigationa sites in 6 European countries are now screening and enrolling patients in the VB C-02 clinical trial. The trial is expected to end the enrolment period in fourth quarter 2021 and plans to report interim clinical data around year-end.

The VB C-02 clinical trial is a multi-centre, open-label clinical trial testing VB10.16, a targeted cancer vaccine, and immune checkpoint inhibitor atezolizumab in patients with advanced HPV16 positive cervical cancer and will enroll up to 50 patients. The clinical trial has the ClinicalTrials.gov Identifier: NCT04405349.